EGFR and non-small cell lung carcinoma: A recent epidemiological study conducted by Surresh K. et al. suggests a greater incidence of synchronous BM in NSCLC patients bearing EGFR/ALK driver mutation/translocations compared to other patients’ subsets (62% vs 57%, respectively; P < 0.05) with median survival not exceeding 14.6 months.